Marion de Jong

Overview

Best Publications

• Somatostatin receptor scintigraphy with [111In-DTPA-d-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients

  E. P. Krenning;D. J. Kwekkeboom;W. H. Bakker;W. A. P. Breeman

  2009
  Citations

• [177Lu-DOTA0, Tyr3]octreotate : comparison with [111In-DTPA0]octreotide in patients

  Dik J. Kwekkeboom;Willem H. Bakker;Peter P. M. Kooij;Mark W. Konijnenberg

  628
  Citations

• Phase I study of peptide receptor radionuclide therapy with [111In-DTPA0]octreotide: The rotterdam experience

  Roelf Valkema;Marion de Jong;Willem H. Bakker;Wout A.P. Breeman

  545
  Citations

• Somatostatin receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors

  Dik J Kwekkeboom;Boen L Kam;Martijn van Essen;Jaap J M Teunissen

  534
  Citations

• Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [177Lu-DOTA0, Tyr3]octreotate

  D. J. Kwekkeboom;W. H. Bakker;B. L. Kam;J. J. M. Teunissen

  519
  Citations

• Plasma Membrane Transport of Thyroid Hormones and Its Role in Thyroid Hormone Metabolism and Bioavailability

  Georg Hennemann;Roelof Docter;Edith C. H. Friesema;Marion de Jong

  508
  Citations

• Somatostatin receptor-targeted radionuclide therapy of tumors: Preclinical and clinical findings

  Marion de Jong;Roelf Valkema;Francois Jamar;Larry K. Kvols

  477
  Citations

• Peptide Receptor Imaging and Therapy

  Dik Kwekkeboom;Eric P. Krenning;Marion de Jong

  475
  Citations

• Safe and effective inhibition of renal uptake of radiolabelled octreotide by a combination of lysine and arginine.

  Edgar J. Rolleman;Roelf Valkema;Marion De Jong;Péter P. M. Kooij

  423
  Citations

• Long-term follow-up of renal function after peptide receptor radiation therapy with (90)Y-DOTA(0),Tyr(3)-octreotide and (177)Lu-DOTA(0), Tyr(3)-octreotate.

  Roelf Valkema;Stanislas A Pauwels;Larry K Kvols;Dik J Kwekkeboom

  417
  Citations

• Radiotherapy with a radiolabeled somatostatin analogue, [111In-DTPA-D-Phe1]-octreotide. A case history.

  E. P. Krenning;P. P. M. Kooij;W. H. Bakker;W. A. P. Breeman

  394
  Citations

• Radiolabelling DOTA-peptides with 68Ga.

  Wouter A. P. Breeman;Marion de Jong;Erik de Blois;Bert F. Bernard

  391
  Citations

• DOTA-NOC, a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5 for labelling with various radiometals

  Damian Wild;Jörg S. Schmitt;Mihaela Ginj;Helmut R. Mäcke

  374
  Citations

• Renal Toxicity of Radiolabeled Peptides and Antibody Fragments: Mechanisms, Impact on Radionuclide Therapy, and Strategies for Prevention

  Erik Vegt;Marion de Jong;Jack F.M. Wetzels;Rosalinde Masereeuw

  327
  Citations

• Combination radionuclide therapy using 177Lu- and 90Y-labeled somatostatin analogs.

  Marion de Jong;Wout A.P. Breeman;Roelf Valkema;Bert F. Bernard

  315
  Citations

• Yttrium-90 and indium-111 labelling, receptor binding and biodistribution of [DOTA0,d-Phe1,Tyr3]octreotide, a promising somatostatin analogue for radionuclide therapy.

  Marion de Jong;Willem H. Bakker;Eric P. Krenning;Wout A. P. Breeman

  313
  Citations

• Radiolabelled somatostatin analogue(s) for peptide receptor scintigraphy and radionuclide therapy.

  E. P. Krenning;M. de Jong;P. P. M. Kooij;W. A. P. Breeman

  302
  Citations

• Optimising conditions for radiolabelling of DOTA-peptides with 90Y, 111In and 177Lu at high specific activities.

  Wouter A. P. Breeman;Marion de Jong;Theo J. Visser;Jack L. Erion

  290
  Citations

• Peptide Receptor Radionuclide Therapy with radiolabelled somatostatin analogues in patients with somatostatin receptor positive tumours

  Martijn Van Essen;Eric P Krenning;Marion De Jong;Roelf Valkema

  290
  Citations

• Peptide receptor radionuclide therapy.

  Eric P Krenning;Dik J Kwekkeboom;Roelf Valkema;Stanislas Pauwels

  129
  Citations